Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 1
Submit an article Journal homepage
182
Views
8
CrossRef citations to date
0
Altmetric
Letters to the Editor

De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy

Jason WestinDepartment of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
&
Peter McLaughlinDepartment of Lymphoma/Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Pages 161-163 | Received 04 Sep 2009, Accepted 09 Sep 2009, Published online: 28 Oct 2009

References

  • Matolcsy A, Chadburn A, Knowles DM. De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct. Am J Pathol 1995;147:207–216.
  • Kipps TJ. The CD5 B cell. Adv Immunol 1989;47:117–185.
  • Lydyard PM, Jewell AP, Jamin C, Youinou PY. CD5 B cells and B-cell malignancies. Curr Opin Hematol 1999;6:30–36.
  • Yamaguchi M, Seto M, Okamoto M, et al De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002;99:815–821.
  • Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009;113:3896–3902.
  • Yamaguchi M, Nakamura N, Suzuki R, et al De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica 2008;93:1195–1202.
  • Yamaguchi M, Ohno T, Oka K, et al De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. Br J Haematol 1999;105:1133–1139.
  • Ennishi D, Takeuchi K, Yokoyama M, et al CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921–1926.
  • Hyo R, Tomita N, Takeuchi K, et al The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma. Hematol Oncol 2009; Apr 8 [Epub ahead of print]. http://www3.interscience.wiley.com/forwardlinking/?oid=122302381

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.